First-in-Class Antibody

Developing Novel Antibody Biologics to Address Unmet Medical Needs

 

Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that that contributes to unmet medical needs.

PBP1510

PBP1710

IDC001

IDC005

: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.

IDC007

: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.

IDC008

: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.

Our groundbreaking accomplishments

First-in-Class

Biosimliar Pipeline

mAbs

Monoclonal Antibodies

Category

Monoclonal
Antibody

Pipeline

PBP1510
(Ulenistamab)

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Phase 1/2a Clinical Trial in Europe and U.S. 50% 50%

Pipeline : PBP1510 (Ulenistamab)

Category : Monoclonal Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Phase 1/2a Clinical Trial in Europe and U.S. 50% 50%

Category

Monoclonal
Antibody

Pipeline

PBP1710
(Anti-CTHRC1)

Indication

Solid Tumors

Development Stage

  • Prearing For preclinical trial 25% 25%

Pipeline : PBP1710 (Anti-CTHRC1)

Category : Monoclonal Antibody

Indication : Solid Tumors

Development Stage

  • Prearing For preclinical trial 25% 25%

bsAbs

Bispecific Antibodies

Category

Bispecific
Antibody

Pipeline

IDC001

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Cloning 20% 20%

Pipeline : IDC001

Category : Bispecific Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Cloning 20% 20%

Category

Bispecific
Antibody

Pipeline

IDC002

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Discovery 10% 10%

Pipeline : IDC002

Category : Bispecific Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Discovery 10% 10%

Category

Bispecific
Antibody

Pipeline

IDC003

Indication

Solid Tumors

Development Stage

  • Discovery 10% 10%

Pipeline : IDC003

Category : Bispecific Antibody

Indication : Solid Tumors

Development Stage

  • Discovery 10% 10%

Category

Bispecific
Antibody

Pipeline

IDC004

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Discovery 10% 10%

Pipeline : IDC004

Category : Bispecific Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Discovery 10% 10%

Category

Bispecific
Antibody

Pipeline

IDC005

Indication

Solid Tumors

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.

Pipeline : IDC005

Category : Bispecific Antibody

Indication : Solid Tumors

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.

Category

Bispecific
Antibody

Pipeline

IDC007

Indication

Critical immune disorders

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.

Pipeline : IDC007

Category : Bispecific Antibody

Indication : Critical immune disorders

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.

Category

Bispecific
Antibody

Pipeline

IDC008

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.

Pipeline : IDC008

Category : Bispecific Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Discovery candidate 15% 15%
Detailed Information

: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.

Category

Bispecific
Antibody

Pipeline

IDC009

Indication

Pancreatic cancer,
Ovarian cancer

Development Stage

  • Discovery 10% 10%

Pipeline : IDC009

Category : Bispecific Antibody

Indication :
Pancreatic  cancer, Ovarian cancer

Development Stage

  • Discovery 10% 10%

Category

Bispecific
Antibody

Pipeline

IDC010

Indication

Immune diseases

Development Stage

  • Discovery candidate 15% 15%

Pipeline : IDC010

Category : Bispecific Antibody

Indication :
Immune diseases

Development Stage

  • Discovery candidate 15% 15%

Fusion Abs

Fusion Antibodies

Category

Fusion
Antibody

Pipeline

IDC331

Indication

Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Pipeline : IDC331

Category : Fusion Antibody

Indication :
Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Category

Fusion
Antibody

Pipeline

IDC332

Indication

Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Pipeline : IDC332

Category : Fusion Antibody

Indication :
Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Expanded Access Policy

At Prestige Biopharma, we are committed to developing safe and effective drugs to improve the health and well-being of patients. We recognize that some patients may have serious or life-threatening conditions and are not able to participate in our clinical trials. For these patients, Expanded Access to investigational drugs may be an option.

Currently, our investigational medicines are in early phase development, and we are not yet providing Expanded Access. We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. We consider this approach to be the best opportunity to bring safe and effective treatments to patients. We encourage any person interested in gaining access to our investigational medicines to consult their physician regarding the possibility of participating in one of our clinical trials. Please review the information about Prestige Biopharma’s ongoing clinical trials found on this website as well as at https://clinicaltrials.gov/.

We wish to assure patients that we are constantly evaluating our policies and procedures. As such, Expanded Access may be reassessed in the future as our investigational medicines advance further in clinical trials and more data to support the safety and effectiveness becomes available.

If you have any questions about our Expanded Access policy or our clinical trials, please contact us at info@prestigebio.com.